Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.

Müssig, Karsten; Wehrmann, Tobias; Dittmann, Helmut; Wehrmann, Manfred; Ueberberg, Bianca; Schulz, Stefan; Bares, Roland; Petersenn, Stephan

Müssig, Karsten; Wehrmann, Tobias; Dittmann, Helmut; Wehrmann, Manfred; Ueberberg, Bianca; Schulz, Stefan; Bares, Roland; Petersenn, Stephan.

Affiliation

Müssig K; Division of Endocrinology, Diabetes, Angiology, Nephrology and Clinical Chemistry, Department of Internal Medicine, University Hospital of Tübingen, Tübingen, Germany. muessig@kaiserswerther-diakonie.de

Clin Endocrinol (Oxf) ; 77(1): 139-45, 2012 Jul.

Article in En | MEDLINE | ID: mdl-22248072

Subject(s)

Carcinoma, Papillary/diagnosis; Carcinoma, Papillary/pathology; Ki-67 Antigen/metabolism; Neoplasm Staging/methods; Thyroid Neoplasms/diagnosis; Thyroid Neoplasms/pathology; Adenocarcinoma, Follicular/diagnosis; Adenocarcinoma, Follicular/pathology; Adult; Biomarkers, Tumor/metabolism; Carcinoma, Papillary/metabolism; Cell Differentiation; Cell Proliferation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Thyroid Neoplasms/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Thyroid Neoplasms / Carcinoma, Papillary / Ki-67 Antigen / Neoplasm Staging Type of study: Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google